• AIRWISE Phase 4 Trial Assessing Various Combos of COPD Therapies Is Underway
  • Bevespi Aerosphere Progressing Toward Regulatory Approval for COPD in Europe, Asia
  • Stem Cells May Offset Damage Done by Smoking to Cells in Lungs, Early Study Says
  • Synairgen to Test SNG001 in Trial for COPD Exacerbations Caused by Viruses
  • Inhaled RPL554 Provides Optimal Delivery for COPD, Other Respiratory Illnesses, Trial Shows
  • Pulmatrix Issued Key US Patents for Inhaled Delivery System and PUR0200 for COPD
  • Phase 3 Trials Show GSK’s Nucala Can Reduce Exacerbations in Specific COPD Patients
  • FDA Approves Triple Combination, Trelegy Ellipta, as Maintenance Therapy for COPD
  • Triple Combo Inhaler Trimbow More Effective than Utibron for COPD, Chiesi Trial Finds
  • Once-a-day Triple Combo Inhaler for COPD Patients Favored for Approval in EU
  • Combination of Verona’s RPL554 and Spiriva Improves COPD Lung Function, Phase 2a Trial Shows
  • Bellerophon Announces Positive Results for INOpulse Therapy for Pulmonary Hypertension Associated with COPD